Q3 2023 Innate Pharma SA Earnings Call

Speaker 1: Thank you for standing by and welcome to the Innate Pharma third quarter 2023 financial results and business update. I would now like to welcome Henry Wheeler, VP Investor Relations and Communications to begin the call. Henry Wheeler, VP Investor Relations and Communications, Inc.

Thank you for standing by and welcome to the innate pharma third quarter 2023 financial results and business update I would now like to welcome Henry Wheeler VP Investor Relations and communications to begin the call Henry.

Henry over to you.

Speaker 2: Thank you very much. Good morning, good afternoon and welcome everyone. This morning, Innate issued a press release for our Q3 financial results and business updates. We look forward to highlighting the progress made during the year to date as well as addressing future goals and milestones.

Thank you very much good morning, good afternoon, and welcome everyone.

This morning, <unk> issued a press release for our Q3 financial results and business updates.

We look forward to highlighting the progress made during the year to date as well as addressing future goals and milestones.

Speaker 2: The press release and today's presentation are both available on the IR section of our website.

The press release and today's presentation are both available on the IR section of our website.

Speaker 2: On slide two, before we start, I'd like to remind you that we'll be making forward-looking statements regarding the financial outlook in addition to regulator and product plan development. These statements are subject to risk and uncertainties that may cause actual results to differ from those...

On slide two before we start I'd like to remind you that we will be making forward looking statements regarding the financial outlook. In addition to regulatory and product planning development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.

Speaker 2: On slide three, on today's call, we will be joined by Monda Mandjubi, our Chief Executive Officer. Then we are pleased to welcome Sonia Carantino, our new Chief Medical Officer, who will cover updates on the QTMAB and MonaLizMap.

On slide three on today's call, we will be joined by Monday <unk>, Our Chief Executive Officer. Then we are pleased to welcome Sonya currently you know, our new Chief Medical Officer, who will cover updates on the kitchen and monitors map.

Speaker 2: We'll then hand the call over to Yanis Morel, EVP of BD and Product Portfolio Strategy, who will then discuss our ANKET and ADC platform updates.

We will then hand the call over to your honest morale EVP of BD and product portfolio strategy, who will then discuss our end caps and ADC platform updates.

Speaker 2: We also have Frederick Lombard, our CFO on the line, for Q&A. Monda, I now hand the call over to you.

Also have Frederic longboard, our CFO on the line for Q&A.

I'll now hand, the call over to you.

Speaker 3: Thank you, Henry. Good morning. Good afternoon, everyone. And thank you for joining us on this call.

Okay.

Thank you Henry and good morning.

Good afternoon, everyone and thank you for joining us on this call.

Speaker 3: Please move to slide four. Slide four is a reminder of how...

Please move to slide four.

So it's always a reminder of how our strategy.

Speaker 3: As an early clinical stage company, our business model centers around three key priorities where we look to drive value from our early R&D efforts to later stage partnerships where it makes sense to do so. Our ambition is to develop innovative drug candidates that contribute to transform cancer care through a strong pipeline of differentiated antibodies.

As an early clinical stage company, our business model centers around three key priorities, where we look to drive value from our early R&D efforts through later stage partnerships, where it makes sense to do so our ambition is to develop innovative drug candidates that contribute to Tulsa.

In cancer care.

<unk> pipeline of differentiated antibodies.

Speaker 3: Firstly, we look to create near-term value driven by our lead proprietary drug candidate, Lacuitima, which is in clinical development for T cell informa, with updates coming at this ASH meeting, including final CTCL and early PTCL data.

Firstly, we look to create near term value driven by our lead proprietary drug candidate <unk>.

Which is in clinical development for T cell lymphoma.

Updates coming at this.

Meeting, including kind of <unk> and early <unk> data.

Speaker 3: As a reminder, our focus remains to leverage the value of our products as much as possible, which will further validate our science and offer capital that we can reinvest to advance our early R&D engine.

A reminder, our focus remains to leverage the value of our products as much as possible, which will further validate our science and offer capital that we can reinvest to advance our early R&D engine.

Speaker 3: We want to make sure that if we can gain valuable competencies via a partner agreement for Equitamap, we will consider that in our development plans for the product as we look to later stage trials, as we have done in the past for other partners as well.

We want to make sure that if we can gain valuable comprehensive via partner game and <unk>, we will consider that in our development plans for the product as we look to later stage trials as we have done in the past for other.

Partnered assets.

Speaker 3: Second, we continue to fuel our pipeline and create longer-term value by leveraging our antibody engineering capabilities to develop innovative molecules with a primary focus on NCAT, our multi-specific NKCL-ENGAZER proprietary platform. And we are pleased to see continued progress.

Second we continue to fuel our pipeline.

Longer term value by leveraging our antibody engineering capabilities to develop innovative molecules with a primary focus on and get our multi specific NK cell engagement proprietary platform and we are pleased to see continued progress.

Speaker 3: with Sanofi presenting various updates for the LEAD NCATE program, SAR 43579 this year at ASCU, at ESMO and also at CAMINAT-

With Sanofi presented various updates for the lead <unk> program <unk> for 40 579 this year at <unk>.

At ESMO and also upcoming at Ash, We also look to move our lead proprietary and get <unk> 65, a one towards phase one trial this year.

Speaker 3: We also look to move our lead proprietary ANKAT, APS 6501, towards Phase 1 trial this year.

Speaker 3: Moreover, as we develop antibody targets for our NCAT platform, we recognize that some of these binders may be more suitable for antibody drug conjugate therapeutics. And we announce some further updates in our ADC pipeline today.

Moreover, as we develop antibody targets for our inkjet platform.

<unk> that some of these binders, maybe more suitable for antibody drug conjugates characteristics, and we announced some further updates in our ADC pipeline today.

Speaker 3: Last but not least, we are building a strong and sustainable foundation for our business with various partnerships across industry and academia. And here our AstraZeneca partnership with Monologemar is progressing well in Langkor.

Last but not least we are building a strong and sustainable foundation for our business with various partnerships across industry and academia and hear our Astrazeneca partnership with <unk> is progressing well in lung cancer.

Speaker 3: Before I hand over to Sonia, on slide five, you have a summary of our pipeline, which shows how we continue to translate our science into a robust portfolio of proprietary and partnered with our partners, and we have learned about what our exploration trauma was like from the editorial side. Yes, sir.

Before I hand over to Sonya on slide five you have a summary of our pipeline, which shows how we continue to translate our science into a robust portfolio of proprietary and partnered assets.

Speaker 3: But it also illustrates how we are executing against our strategy with our lead proprietor assets like Kitama and get an emergent ADC.

It also illustrates how we are executing against our strategy with our lead proprietary assets likely to Matt.

At any measured adcs superheated by partnered products with Astrazeneca Sanofi and Takeda from late two early stage development, we anticipate a series of potential clinical data readouts and catalysts in the upcoming couple of years as our R&D engine.

Speaker 3: supported by partner products with Afrozineca, Sanofi, and Takeda from late to early stage development.

Speaker 3: We anticipate a series of potential clinical data readouts and catalysts in the upcoming couple of years as our R&D engine looks to leverage our scientific know how to create sustainable data.

Looks to leverage our scientific knowhow to create sustainable business.

Speaker 3: I would like now to pass the call over to Sonia, who will review the progress made with our portfolio, starting with Liquitamab, our most advanced proprietary asset.

I would like now to pass the call over to Sonya, who will review the progress made with our portfolio starting with <unk>, our most advanced proprietary assets Sonya.

Speaker 4: Thank you, Wunder. On slide six, let me summarize the progress we are making with Lacoutamat, our anti-here 3D L2 antibody.

Thank you Linda.

Slide six let me summarize the progress we are making with liquid amongst our anti <unk> two antibody.

Speaker 4: In T-cell lymphoma, we are pursuing a fast-to-market strategy for Lakutamab in the niche indication of Caesarean syndrome, where Lakutamab was granted U.S. fast-track designation and EU prime designation in 2020.

In T cell lymphoma, we are pursuing as fast to market strategy for like with a map in the niche indication of <unk> syndrome.

<unk> was granted us fast track designation and EU Prime designation in 2020.

Speaker 4: We have expanded past Cesare syndrome to mycosis fungoides, and we have seen encouraging preliminary data from our faithful trial in both diseases.

We have expanded.

Syndrome home ecosystem joined us and we have seen encouraging preliminary data from our phase II trial in both diseases.

Speaker 4: For the Salary Syndrome, we announced early this month that final data is due at ASH next month. And we expect to have final data announced for the mycosis fungoides later this year.

This is a syndrome, we announced earlier this month that final date is did you at Ash next month.

And we expect to have final they dine out for them ecosystem growing. This later this year.

Speaker 4: Finally, we continue to enroll patients with refractory relapse, peripheral tifilinoma in phase 1b with lacutamab monotherapy, and in a randomized phase 2 with lacutamab in combination with chemo, and some updates will also be presented at ASH.

Finally, we continue to enroll patients with refractory relapse, a resale of T cell lymphoma in phase one.

With La Quinta monotherapy and in a randomized phase II with <unk> in combination with chemo and some update will also be presented at ash.

Speaker 4: We announced earlier this month that the U.S. FDA placed Lacutamab trial on a partial clinical hold due to one case of hemophagocytic lymphocytosis in the Talomac trial.

We announced earlier this month the U S. SDI placed luck with MF trial on a partial clinical hold due to one case of Haemophile received the employees just scientologists in the Telemark trial.

Speaker 4: And we are currently undertaking efforts to address the FDA request and carried out an in-depth analysis of the HLH case, together with the steering committee with independent experts, which point to the fact that the case is related to the aggressive disease progression.

We are currently undertaking efforts to address the SDN and.

<unk> carried out in that analysis.

<unk> together with the steering committee with independent experts, which point to the fact that the cases related.

The aggressive disease progression.

Speaker 4: On slide seven, we have the final efficacy data in Caesarean syndrome that have been accepted for oral presentation at ASH.

On slide seven.

We have the final efficacy data in salary syndrome that have been accepted for oral presentation at ash.

Speaker 4: The abstract details that in this heavily pre-treated, post-mogalizumab patient pool, with a medium number of six prior therapies, the global overall response rate was an encouraging 37.5%, as can be seen on the waterfall plot on the slide. And an overall response of 46.4 in skin and 48.2% in blood.

Chuck details that can be it's heavily pre treated cost mogul easel non patient pool with a median number of six prior therapies. The global overall response rate wasn't an encouraging 37, 5% as can be seen on the waterfall plot on the slide and.

And then overall response of 46 four in skin and 48, 2% in line.

Speaker 4: We also observed the clinical benefit rate of 87.5% and the medium progression pre-survival of eight months.

We also observed a clinical benefit rate of 87, 5% and the medium progression free survival of eight months.

Speaker 4: It was very encouraging to see efficacy confirmed in the larger phase two trial in these late line patients together with a favorable safety profile. We look forward to sharing the full presentation of the ASH Annual Meeting in San Diego and sharing the data with the regulatory authorities.

It was very encouraging to see a secrecy confirmed in the larger phase II trial in these late line patients together with the <unk> safety profile.

We look forward to sharing the full presentation at the Ash annual meeting in San Diego and sharing the data with the regulatory authorities.

Speaker 4: Next, I would like to update you on monolizumab, an asset we have licensed to AstraZeneca. To remind you, monolizumab is an anti-NKG 2A, which acts upon the checkpoint pathway to potentiate NK cells and activate tumor infiltrating CD80 cells.

Next I would like to update you on our lithium up enough that we have licensed to astrazeneca.

And mind, you when our lithium and these are non TNK.

So any which upon the checkpoint pathway to potentiate NK cells, and escalate tumor infiltrating CDA T cells.

Speaker 4: On the slide, you can see an overview of the late stage development plan for monalizumab in lung cancer.

On designing you can see an overview of the late stage development plan for Mona Lisa lumber in lung cancer.

Speaker 4: Building upon the data of the Phase II COAST trial, AstraZeneca commenced Pacific-9, a Phase III trial of duralmabalone, or combined with monolizumab or oleclumab, an anti-CD73 antibody, as consolidation therapy for patients with unresectable stage III non-smortheland cancer who have not progressed after concurrent chemo radiation.

Building upon the data of the phase II coast trial Astrazeneca commenced specific nine.

<unk> trial of door volume alone or combined with <unk>.

Or like Lamont and anti CD 73 antibody as consolidation therapy for patients with Unresectable stage III non small cell lung cancer, who have not progressed after concurrent chemo radiation.

Speaker 4: The Faith to Coast Study had a similar study design to the Pacific Nine. The result of an interim analysis after a median follow-up of 11.5 months were published in Journal of Clinical Oncology in 2022.

The phase two study had a similar study design to the Pacific nine there is no sort of an interim analysis off time median follow up of 11 five months.

Competition Jordan of clinical oncology in 2022.

Speaker 4: The results showed that the primary endpoint of confirmed overall response rate by investigator assessment was 35.5% with dervalomab plus monolizumab versus 17.9% with dervalomab alone.

The results showed that the primary endpoint of confirmed overall response rate by investigator assessment was 55, 5% with development plus Mona Lisa.

$17 nine with the robalo months alone.

Speaker 4: PFS was prolonged for Dorvalumab plus Monalizumab versus Dorvalumab alone with a hazard ratio of 0.42.

Yes that was prolonged for <unk> plus Mona Lisa.

Versus the sort of volume alone with a hazard ratio of <unk> 42.

Speaker 4: And the 12-month PFS rate was 72.7 with durvalumab plus monalizumab versus 33.9 with durvalumab alone.

And the 12 months PFS rate was $72, seven which drove bottom plus Mona Lisa.

That's the $33 nine with development alone.

Speaker 4: The AstraZeneca sponsored Neocost 2 study is also underway in an earlier stage in lung cancer, evaluating Monalizumab and dorvalumab with chemo in the new vaginome setting.

The Astrazeneca answer Neil cost. Two study is also underway in an earlier stage in lung cancer, and evaluating lithium up and volume up with chemo in the new module and setting.

Speaker 4: I will now hand over to Yanis to cover our Ankit and ADC platform.

I will now hand over to Jan is to cover our anchored and ADT platform.

Thank you was going down.

Speaker 5: On slide 9, I wanted to highlight our proprietary NKCEL Engager platform that we call NKCEL.

On slide nine I wanted to highlight our propitiatory NK cell on gauge of platform that we call MK.

Speaker 5: I'm Kat standing for antibody based and queselles engagers terra...

And get standing for antibody based and <unk>.

Speaker 5: and get the versatile feed-for-purpose technology made of antibody building blocks that is creating a new class of multi-specific engager to induce synthetic immunity against cancer.

And get divested dial fit for purpose technology made of antibody building blocks that is creating a new class of multi specific MDA, Joe to induce synthetic immunity against cancer.

Speaker 5: The technology platform, which is leveraging our scientific expertise in the NkCEL space, is an engine for us to create a series of drug candidates addressing multiple tumor targets.

Technology platform, which is the very Jing, our scientific expertise in the NK cell space is an engineering prowess to create a series of drug candidates addressing multiple tumor targets.

Speaker 5: The backbone of the ONCAT platform consists in the unique engagement of the activating NK cell receptors, NKP46, and CD16 on the NK cells, which allows for optimal harnessing of the NK cell function.

The backbone of young get platform, consisting the unique engagement of the activating and kits that are a safe dose and keep your 46 and 2016 on the NK cells, which allows for optimal auditing of the NK cell function.

Speaker 5: In addition, this mechanism can be further increased by the addition of the IL-2 variants in order to induce NK cell proliferation.

In addition, this make any of them can be further increased by the addition of the IL two volumes in order to induce NK cell proliferation.

Speaker 5: On slide 10, I wanted to share our enthusiasm for this.

On slide 10.

I wanted to share our enthusiasm for this platform.

Speaker 5: As you can see, our pipeline of ANCAT molecules is significantly growing, with Sanofi having now licensed three molecules, with two of them in the clinic, and having an option on two other undisclosed targets.

As you can see our pipeline or won't get molecule is significantly going with Sanofi I think in our license <unk> molecules with two of them in the clinic and have been an option on two other undisclosed targets.

Speaker 5: Also, our most advanced proprietary NGET, IPH65, which is targeting CD20 and is armed with an IL-2 variant, has cleared IND and is currently starting phase.

Also our most advanced <unk> <unk> 65, which is targeting CD 20, and is armed with a 92 volumes as clear on the IMD and he's currently stocking phase one.

Speaker 5: In addition, we have several proprietary preclinical programs against multiple targets.

In addition, we have similar appropriately preclinical programs against multiple targets.

Speaker 5: On the right panel, you can see the detailed mechanism of action of the unkept molecules, which we have published in a couple of articles in high-impact journals.

On the right panel you can see the detail in Mckinney of action of the <unk> molecule.

Which we established in a couple of articles in high impact journals.

Speaker 5: Our natural biotechnology paper, published in January this year, describes a joint work with Sanofi on the CD123 NK cell engager, IPH6101, or SAR579.

Our our nature Biotechnology Paypal published in January of this year. These kinds of joint work with Sanofi on the CD, one to <unk> 61, and one <unk>.

579.

Speaker 5: SAR579 is a co-engaging NKP46 and CD16 on NK cells, and therefore triggers potent antigen-dependent killing of IML tumors, as well as production of key cytokine for the antitumor immune response, but without inducing the systemic cytokine release, which is a dose-limiting feature of the T cell engager.

<unk> 79 is a core engaging and <unk> 46, and <unk> 16 on NK cells, and therefore, three gas potent antigen dependent killing of tumors as well as production of key cytokine, while the anti tumor immune response, but without inducing the systemic cytokine release, which is a dose.

Beating feature of the T cell <unk>.

Speaker 5: Moreover, we have shown in our cell report medicine paper that the incorporation of an IL-2 variant into a non-CAT induce a preferential NK cell proliferation within the tumor microenvironment, increasing therefore the number of anti-tumor effector NK.

Although we have shown in our February bulk medicine, peyto that incorporation of the 92 valiant into a non get induce a quicker uninsured NK cell population within the tumor microenvironment, increasing therefore, the number of NTT <unk> NK cell.

Speaker 5: On slide 11, you can see an overview of the clinical data presented this year at ASCO and ESMO, and also the abstract that has been accepted for presentation at this year's ASH meeting for the CD123-ENQED program, also named SAR443-579.

On slide 11.

You can see another view of the clinical data presented this year at <unk> and ESMO and also the abstract has been accepted for presentation at Ash meeting for the TD wants to see and get Poland also named <unk> for Pete type 79.

Speaker 5: In the apps in the ASH abstract, we were encouraged to see further single agent activity and safety for the SAR579 in relapse prefractory MLP.

In the apps in the Ash abstract we were encouraged to see Philadelphia and got agent activity and safety for the sub 579 in relapsed refractory AML patients.

Speaker 5: Additional complete responses were observed, with now five complete responses out of 15 patients treated at the one-mic-talk-tick dose level.

Additional complete responses well itself with no five complete responses out of 15 patients treated at the one of those neighborhoods.

Speaker 3: SAR579 was well-tolerated at dose up to 6 mg per kg with no dose-limiting toxicity observed and only two grade 1 TRS observed out of 43 patients. We look forward to the full presentation.

<unk> 79 was well tolerated at doses up to six months with no dose limiting toxicity of cell and only two grade one.

Of sales out of our top 43 patients we look forward to the full presentation at ash.

Speaker 5: In the ESMO update, two of the complete responders previously reported at ASCO remain in remission after 8.8 and 12.2 months after treatment, highlighting the durability of this response.

In the ESMO update two of the complete responders could you see reported at Agco remain in remission after eight eight and $12 two months after treatment.

In the July ability of these responses.

Speaker 5: The FDA awarded SAR579 fast track designation in May and Sanofi plans to evaluate further dose levels. We look forward to further updates from Sanofi in due course.

Yes, well, it's up 579 fast track designation in May and Sanofi plans to evaluate those lasers, we look forward to further updates from Sanofi in due course.

Speaker 5: On slide 12, you can see a summary of our Sinophi Alliance. In 2016, we signed an initial agreement for two Enquete molecules worth up to 400 million euros in milestones, among which we announced 16 million today.

On Slide 12, you can see a summary of our <unk> Alliance in 2016, we signed an initial agreements of two <unk>.

Well up to 400 million Euro in my students, among which we announced 16 million to date.

Speaker 5: Both programs have progressed with SARS-5-79 and SARS-5-14 now in phase 1 clinical type.

Both programs I apologize, we stockpiled 79, and south site now in phase, one clinical or tier in.

Speaker 5: In December last year, we signed a further agreement whereby Sanofi licensed the IPF62 ANCAD program targeting B7H3, a solid tumor target, with an option on two other undisclosed targets.

In December last year, we signed a further argument whereby Sanofi license. The Ikea 60 to one get program targeting disadvantage Street, a solid tumor target with an option on two other undisclosed targets.

Speaker 5: Sanofi paid €25 million upfront, with €1.35 billion in total milestone plus royalties.

<unk> paid $25 million upfront with a $1 35 billion in total milestone plus y.

This now takes the total milestone package of our collaboration up to $1 75 billion plus why.

Speaker 5: We look forward to working with Sanofi as we bring this new Hunkhead to the clinic.

We look forward to working with Sanofi as we bring this new one gets to the kidney.

Speaker 5: Slide 13 highlights our growing ADC pipeline.

Slide 13 highlights our growing ADC pipeline as.

Speaker 5: As we continue to develop next-generation therapeutics utilizing our antibody engineering platform, we find that for some tumor targets, we can generate antibodies more suited for ADC than for ONCAT, especially when they show good internalizing progress.

As we continue to develop next generation therapeutics utilizing our antibody engineering platform, we find that folks some tumor targets, we can generate antibodies most suited for ADC and so on get especially when they show good internalizing poverty.

Speaker 5: Our agreement with Takeda in the field is providing a validation to this research approach and highlights our capability to generate differentiated ad say candidates.

Our agreement with Takeda in the field is providing a validation to this <unk> approach and highlights our capability to generate differentiated <unk> candidates.

Speaker 5: On slide 14, I wanted to give you some more details on our next info targeted ADC, IPH45, as we prepare the IND.

On slide 14, I wanted to give you some more details on our <unk> <unk> targeted ADC IP edge 45, as we pay out the iron.

Speaker 5: We have selected an antibody targeting a unique epitope, which is not competing with the one of amphortuma vedota, or PATSEV, and we are using a TOPO1 payload with a stable and hydrophilic linker.

We have selected an antibody targeting a unique epitope, which is not competing with the one of <unk>.

Yes.

And we are using a total one payload with established stable and ultra clean cow.

Speaker 5: These key scientific attributes for IPH45 translate into features that have the potential to maximize the Nektin-4 opportunity across various solid tumors.

This key scientific attributes for IP, aged 45 conflate into features that we have that have the potential to maximize the nicotine for all <unk> instruments.

Speaker 5: First, in preclinical models, IPH45 has demonstrated a larger therapeutic index and a longer PK compared to enforcement of beta-10, which could improve the dosing regimen and aim at a better safety profiling pace.

First in preclinical models <unk> 45, as demonstrated a large up to <unk> index and the loan guarantee compare.

Compared to <unk>, which could improve the dosing regimen and aimed at a better safety profile in patients.

Speaker 5: Second, as shown on the graph on the right, IPH45 shows strong anti-tumor efficacy in preclinical in vivo model, resistance to amphotumab-bedotin, suggesting that IPH45 could be active in patient refractory or relapsing after EV or other MMI-based therapy.

As shown on the graph on the right <unk> 45 showed strong antitumor efficacy in preclinical in vivo model assistance to our 40, <unk> Middletown, suggesting that Ips 45 could be active in patients refractory or relapsing after EV order MMA based therapeutics.

Speaker 5: Last, the bystander effect of the TOPO1 payload selected, together with the increased therapeutic index, suggests that IPH45 could address multiple tumor types across the various Nektin-4 expression levels.

Last the bystander effect of the total one payload selected together with the increased opportunity index suggest that <unk> 45, kudo device multiple tumor types, because the values <unk> four expression levels.

Speaker 5: Altogether, IPH45 has a unique profile with promising preclinical data that could translate into better patient outcomes across indications and lines of treatment. I will now turn to Mondaire for a summary.

Altogether <unk> 45, as a unique profile with <unk> preclinical data that could translate into better patient outcomes across indications and lines of treatment.

Now down to Mon Therefore assembly.

Thanks Sharon.

Speaker 3: Please move to slide 15 where we highlight the updates. We are looking forward to at ASH in a few weeks time in San Diego where we will share the L'AcquitaMap updates and Salufi will present SAR-579-Ankit update.

Please move to slide 15, where we highlight the updates we are looking forward to at Ash in a few weeks' time in San Diego, where we will share the <unk> dates and Sanofi will present.

579 and get updates.

Speaker 3: We also plan to host a KOL call on site during the conference, and we look forward to further discussing the LACUTA map data with you.

We also plan to host a KOL call on site during the conference and we look forward to further discussing the lucky to map data with you.

So let me summarize now on.

Maybe.

Speaker 3: If you move to slide 16, you may be familiar with this slide. We continue to work diligently to execute across all our strategic pillars. And we believe that we are laying the foundation to drive near and long-term value.

If we move to slide 16.

You may be familiar with this slide we continue to work diligently to execute across all our strategic pillars, and we believe that we are laying the foundation to drive near and long term value.

Speaker 3: Looking at our clinical program, we expect to achieve a number of milestones over the next two years.

Looking at our clinical program, we expect to achieve a number of milestones over the next two years.

As you've heard from Sonya.

Speaker 3: Lacutumab Phase II Telemac final Cesare syndrome and MF data is due at the end of this year, in addition to initial PDCL data.

<unk> phase II Telemark final is already syndrome in MF data is due at the end of this year.

In addition to initial purchase shell data.

Speaker 3: In parallel, we continue to develop our NCAT platform further reinforced by our partnership with Sanofi, and we are very encouraged by the initial clinical data presented at Congress this year, and the IND clearance for our proprietary NCAT, which is progressing toward the clinic. We believe that these represent a natural evolution of our platform.

In parallel we continue to develop our NK platform further reinforced by our partnership with Sanofi and we are very encouraged by the initial clinical data presented at Congress is this year and the IND clearance for our proprietary and kit, which is progressing toward the cliff.

We believe that this represents a natural evolution of our platform.

Speaker 3: Last but not least, for monolizumab, the lung cancer trials are underway, and we continue to advance the adenosine pathway agents in the clinic where the phase two for APH5201 in early lung cancer is underway. Let's move to the conclusion slide, please.

Lots about northeast from <unk>, the lung cancer trials are underway and we continue to advance the adenosine pathway agents in the clinic, where the phase III for Aps 50 to a one in early lung cancer is underway.

Okay.

Let's move to a conclusion slide please.

As you can tell we continue our exciting journey originate we look to build our business to create value for patients and stakeholders.

Speaker 3: We look to build our business to create value for patients and stakeholders.

Speaker 3: In summary, we have positioned innate pharma for the future with our strategy and made meaningful progress across all three strategic pillars.

In summary, we have positioned in a pharma for the future with our strategy and made meaningful progress across all three strategic pillars.

Speaker 3: With our R&D engine and antibody engineering expertise, our science is producing more candidates to progress to the clinic.

With our R&D engine and antibody engineering expertise, our science is producing more candidates to progress through the clinic.

Speaker 3: So we are developing alone, some we are developing alone and some...

So we are developing alone. Some we are developing are known and some partnerships.

Speaker 3: We have a focus on our NK cell engager platform, NKET, as well as antibody drug conjugate.

We have a focus on our NK cell engagement platform and kit as well as antibody drug conjugates.

Speaker 3: But in parallel, our late-stage portfolio continues to advance, and as we look to maximize the late-stage portfolio assets of both L'Aquitama and Monalisa.

But in parallel our late stage portfolio continues to advance and as we look to maximize the late stage portfolio assets of.

Both liquid and more or less demand.

Speaker 3: Second, our partnership strategy continues to evolve, with the Takeda deal adding to those of AstraZeneca and Sanofi.

Second our partnership strategy continues to evolve with the Takeda deal, adding to lose of Astrazeneca and Sanofi.

Speaker 3: Finally, we have, we continue to carefully manage our resource so we can continue our sustainable business and invest in progress in our pipeline. I'm very pleased that we continue to have a strong cash position with a runway into the second half of 2020.

Finally, we have we continue to carefully manage our also so we can continue our sustainable business and invest in progressing our pipeline and very pleased that we continue to have a strong cash position with a runway into the second half of 2025.

Speaker 3: So collectively, we are driving value across our business and finally advancing our goal to deliver innovative medicine to patients. We look forward to keeping you updated on our progress.

So collectively we are driving value across our business and finally advancing our goal to deliver innovative medicines to patients. We look forward to keeping you updated on our progress.

Speaker 3: That concludes our prepared remarks. We will now open the call to questions.

That concludes our prepared remarks, we will now open the call to questions.

Speaker 1: At this time I'd like to remind everyone, in order to ask a question press star then the number one in your telephone keypad. We'll pause for just a moment to compile any questions.

At this time I would like to remind everyone in order to ask a question Press Star then the number one on your telephone keypad.

Pause for just a moment to compile any questions.

Speaker 1: Again, if you'd like to ask a question, please press star 1 on your telephone keypad now.

Again, if you'd like to ask a question. Please press star one your telephone keypad now.

While price it can we can we take the first question. Please.

Speaker 1: Our first question comes from the line of Dana Graybosh with Lerink Partners. Please go ahead.

Our first question comes from the line of Dana Gray boss with Leerink partners. Please go ahead.

Speaker 6: Hi, this is Rabib on Sirdana. What is your view of SAR443579 or IPH61's dosing profile to date, and how do you think that reads through to the ANCET platform more broadly? Thank you.

Hi, This is <unk> on for Dana.

What is your view.

$443, $5 99, or IPA 61 dosing profile to date.

How do you think that reads through to the <unk> platform more broadly thank you.

Yes.

Speaker 3: Thank you. Probably Yanis is the best person here to answer the question about the dosing profile for 61 and beyond that, of course, the rest of our NCAT drug candidates.

Thank you.

Probably yes, and this is the best person here to answer your question about the dosing profile for 61 and beyond that of course, the rest of or <unk>.

Drug candidates.

Speaker 5: Yeah, the data that have been presented by Sanofi up to date, the ASCO, but also more recently at the ESMO showed that the clinical responses were observed at the cohorts where the maximum dose was one mcg per kg. The ASH abstracts also report additional response at one mcg per kg, but not at higher doses.

Yes, the data that has been presented by Sanofi are up to date.

The score, but also more recently at the at the ESMO showed that dirty Nikola responsive, where upsell that the costs are where the maximum dose was one Nick Beal keg.

The ash abstract also report additional restaurants at Nic they'll kick, but note that higher doses.

Speaker 5: suggests a potential base shape effect on the drug. And like you can see in the abstract, more details on that should be presented at the ash.

This.

<unk> as a potential base shape the effect on the Oregon.

You can see in the abstract more detailed on that it should be presented at the ash meeting.

Speaker 5: But if you look back at the ESMO presentation, there were blast reduction at all doses tested. What it tells us is that we may for, I mean, on a target-per-target basis, you know, because a multispecific engager is binding on one side to the tumor, but on the other side, on the NK cell.

If you look back at the ESMO presentation their way up.

Production at all.

The doses tested.

What it says is that.

We may four.

Target targets basis.

Because.

Specific on Gateway is binding on one side to the tumor but on the other side on the NK cells.

Speaker 5: you may adapt the dose in the phase 1 from one target to the other. But, you know, it's not something that is unusual. There have been also some example recently, for example, with the tarlatan map from Amgen where the 10 mg flat dose showed better results than the 100 mg flat dose in small cell lung cancer.

You may add up the dose.

In the phase one from one targets to the other but it's.

It's not something that is unusual.

For some example.

For example, with the <unk>.

<unk> from Amgen.

<unk> 10.

Flat dose showed better results than the flat dose.

In small cell lung cancer.

Thank you Denise.

Speaker 1: Our next question comes from the line of Yigal Yashomovitz with Citi. Please go ahead.

Our next question comes from the line of Yigal <unk> with Citi. Please go ahead.

Speaker 7: team this is Carly on for you all thanks for taking our question

Hi, Tim This is Carly on for Yigal, Thanks for taking our questions for the crude map, we wanted to get your latest thinking on the next steps for see PCL.

Speaker 7: For LacudaMab, we wanted to get your latest thinking on the next steps for CPCL. I think in the past you've talked about the potential for the cesarean cohort to support an accelerated approval pathway. So just curious if that's still part of the plan and then what different scenarios could look like for mycosis and goitus as well.

In the past you've talked about the potential for this February cohort to support an accelerated approval pathway.

Curious if that's still part of the plan and then what different scenarios could look like for Mycosis go ahead us as well.

Future studies. Thank you.

Speaker 3: Yeah, I'm gonna take the question. So

Yes.

I'll take the question.

So.

Speaker 3: As you know, our aim is to pursue the development of Lacrytamide beyond the Caesarean syndrome. The microcystic-fungoides cohort in the TELEMEC trial is a signal detection study because we didn't generate previously data outside Caesarean syndrome. So this is, you know, the first

As you know our aim is to.

Pursue the development of electric.

Beyond this as <unk> syndrome.

<unk>.

Michael just won't grow this cohort in the <unk> trial is.

Signal.

Detection study because we didn't.

Generate.

Previously data outside <unk> syndrome. So this is the first.

Speaker 3: prospective, controlled phase two study to generate additional data outside CIZARI. And of course, our main goal is to make sure that L'Equitamab gets to the patient who needs it.

Perspective.

Controlled phase II study to <unk>.

Additional data outside CRE and of course, our main goal is to make sure that like with them up gets to the patient who needs. It.

Speaker 3: as quickly as possible. It's clear that in the Cesare syndrome, given the orphan drug designation, or of course the fast-track designation, as well as the prime designation in Europe , there is a significant unmet medical need, especially in those patients who are progressing after two prior line of therapy, especially after Mocha-Muljimab. And clearly the emerging data that we are generating and about to present to ASH will be discussed with the FDA in terms of potential suitability for accelerated approval and also the confirmatory phase three strategy, building, as I said, on the existing fast-track and desires for clerical relief for designation.

As quickly as possible it is clear that in this <unk> syndrome given.

The orphan drug designation or of course, the fast track designation as well as the prime designation in Europe. There is a significant unmet medical need, especially in those patients who are.

Progressing after.

Two prior lines of therapy, especially after mogul managing up and.

Clearly the emerging data that we are.

<unk> generated and about to present too.

We will be discussing with the FDA in terms of potential suitability for exited the approval and also the confirmatory phase III strategy.

Or as I said on the existent first hike enough of designation.

Speaker 3: As you know,

As you know.

Sure.

Speaker 3: Our business model, of course, is clear. Further development and registration of this asset is something we intend to progress via partnership, leveraging the capabilities and expertise of a partner in area that we do not have existing capability of expertise. This will allow us to focus on our proprietary and innovative portfolio, and we will provide you updates as and when we can, and trust that you understand the sensitivity of any potential partnership prior to formal announcement.

Our business model of course.

It's clear further development and registration of this asset is something we intend to progress via partnership leveraging the capabilities and expertise of our partner in area that we do not have existing capability of expertise. This will allow us to focus on our proprietary and innovative portfolio and we will provide you updates.

As and when we can and trust, which I understand the sensitivity or any potential partnership prior to formal announcement.

Speaker 8: I also know that in our discussion with the FDA, we will certainly discuss about the confirmatory phase 3 trial, which of course will be including not only cesarea but clearly other form of CTL in particular mycosis from COVID S.

So no debt.

In our discussion with the FDA we will.

Certainly discuss about the confirmatory phase III trial, which of course will be including not only says already but clearly other form of <unk> in particular, Microsoft's funko readers.

Okay.

Okay got it that's really how I hope you guys are asking a question.

Speaker 7: Yes. Yes. Perfect. Thank you. And then just a follow-up question, maybe on the NECDN for ADC program. It seems like you think there's potentially an opportunity in the post-PADSEV setting here. I'm just wondering if you could talk a little bit more about early thoughts on the development strategy and then just timelines for bringing that.

Yes, Okay perfect. Thank you and then just a follow up question maybe on that the next <unk>.

<unk> <unk> ADC program.

Seems like you think there's potentially an opportunity in the post pads.

Getting here just wondering if you could talk a little bit more.

About early thoughts on the development strategy and then just timelines for bringing that into the clinic. Thank you.

Speaker 5: Yes, yes, indeed, by actually switching the class of payload and going after topo1 inhibitor, we are seeing some pretty good efficacy in preclinical models after PAD-Sev, and I mean models that are resistant to PAD-Sev.

Yes, yes indeed.

Actually switching the cast of payload and going after it.

Topo one inhibitor.

We are seeing some pretty good efficacy in preclinical models.

<unk> and <unk>.

That obviously tend to headset.

Speaker 5: And what is also encouraging for this approach is that there are some reports in the literature showing that patients who are relapsing or to PACEV are not losing the expression of the antigen. So the antigen is still there, but it's more a mechanism of resistance against the payload that is developing within these patients.

And what you saw.

Encouraging for this approach at that there are some reports in the literature showing that.

Patients who are relapsing off.

200 <unk>.

Losing the expression of the antigen so at the end of January.

But it's more of a mechanism of resistance against the payload that is.

Looking within these patients. So this is clearly one.

Speaker 5: So this is clearly one path that we at some point would like to explore in our clinical development plan, but it's not only the only one as the next info can be also expressed in several other solid tumors that are so far showing pretty limited activity with the path set. And this leveraging the wider and larger therapeutic index of our company.

One path that we at some point, we'd like to we're exploring now clinical.

Clinical development plan, but it's not only the <unk>.

Only 119.

<unk> four can be also expansion instead of oil or the affiliate channels that so far showing pretty limited activity with the bedside and stabilizing the wider.

Wider and larger therapeutic index.

Of our compound.

Speaker 5: And in terms of timing, we are actually working to file an ING next year with this one.

And in terms of timing.

Actively working to.

To file an anda nextgen and this one.

Okay, great. Thank you for thank you.

Speaker 1: Again, as a reminder, the floor is now open for your questions.

Again as a reminder, the floor is now open for your questions to ask a question at this time. Please press star one on your telephone keypad.

Speaker 1: To ask a question at this time, please press star 1 on your telephone.

Speaker 1: Our next question comes from Arthur He with HC Wainwright. Please go ahead.

Our next question comes from Arthur He with HC Wainwright. Please go ahead.

Speaker 9: Hey everyone, this is Arthur Ong for Arcade. Thanks for taking my question. So I just wonder for the 579 data at the ASH.

Hi, everyone.

One four okay. Thanks for taking my question.

So I just.

Wonder for the.

579 data at Ash.

Speaker 9: Could you give us more color on the safety side, especially for that grade four case, grade four neutropenia? Could you give us more color on that?

Could you just give us more color on the safety side, especially.

That's great for case going for neutropenia could you give us more color on that.

Oh.

Speaker 3: So I'm not sure I'm getting the question right. So far actually based on the abstract, the safety profile of 579 or API 6101 was reported as favorable. There were names of stories that were not originally fully expressed in wrists, in different things of the universe, but they were the numbers not set yes.

So I'm not sure.

I'm getting the question right.

So far actually based on the apps tagged.

The safety profile.

Type 79, or <unk> 61, and one was reported as favorable.

There were.

One.

Speaker 3: great for neutropenia but we don't have details more than what is in the abstract so clearly something to

Grade four neutropenia, but we don't have details more than what is in the abstract so clearly.

Something too.

Speaker 3: ask when the data will be presented at ASH in a couple of days. But a reminder, those are heavily pre-treated patient, median number of prior line of therapy.

When the data will presented at Ash in a couple of days.

Those are heavily pre treated patient median number of prior lines of therapy.

Speaker 8: Most of the patients who received venetoclax, a significant number went through stem cell transplantation. And this is, of course, interesting to better understand the reason of this grade four neutropenia, whether it is disease-related or...

Most of the patients receive is Veneta Clark's cigna.

A significant number went through <unk>.

Cell transplantation and this is of course.

Interest and to better understand the reason of this.

Great for neutropenia, whether it is this is related.

Drug related.

Speaker 9: I think. Thanks for that. My second question is, I'm just curious, when you are evaluating different binders, which is suitable for the NCAT or versus the ADC platform, what kind of criteria or selection preference for each side? Just curious from your perspective. Thanks.

Thanks for the let's.

My second question is.

I was just curious where you are very different binder, which.

Which is typical for the.

The.

And Kent or versus the ADC platform.

What kind of criteria or selection preference for each side just curious from your perspective. Thanks.

Okay.

Speaker 8: I'm going to hand over to Yanis to give you a more detailed answer, but as we explained in the past, of course, some of the binders are more suitable for NCAT, the ones that internalize actually are by design favorable candidates for the ADC, but Yanis can give you more color on our thinking on how we select those binders.

I'm going to hand over to Dennis to give you a more detailed answer but as we explained in the past of course.

Some of the binders are.

A more suitable for.

<unk>.

Yes.

And yet the one is that internalized actually.

By design.

Favorable candidates for the ADC, but it can give you more color on our.

Thinking on how we select to bind us.

Speaker 5: Um, yes, it's, uh, but it's obviously a target by target discussion because you know that some targets do have this property to internalize and some

Yes.

But it's obviously a target by target discussion because you know that some targets do as this property to internalize and some donuts.

Speaker 5: And depending on this property of the target.

And depending on this.

This <unk> of the target.

Speaker 5: the structure and the ability to generate.

This culture and the ability to generate.

Speaker 5: a binder that are hitting the target at different epitopes.

That's how it being the target.

Different epitopes.

Speaker 5: We can generate binders that are rather staying at the cell surface and are pretty good candidates for an unkept molecule and others that do internalize and this we are screening that.

<unk> generates binder.

No.

Staying at the sales your face and a pretty good candidates.

Ill get molecule and although thats doing it on their eyes and this we are seeing that in.

Speaker 5: in vitro with pretty classical methods that are widely used by people developing ADCs.

Vito with pretty catch coordinator.

Widely used by many people developing adcs.

Speaker 5: and we are checking the ability to induce the direct killing based on the expression level of the target.

We are checking the ability to induce the J Keating based on the expression level of the target. So there are so many more amit that's worth taking into account.

Speaker 5: So, there are also many more parameters that we are taking into account, like the medical need, the development path, and the potential opportunity for this molecule. But in terms of antibody characteristics, this is really one we are using in one of our early filters.

I mean, you could need the developing fast and.

And the potential opportunity for visa.

If all these Medicare but in terms of antibody characteristics. This is really one where.

We are using in one of our LTC sales.

Thanks for taking my question.

Yes.

Yes.

Speaker 1: Our next question comes from the line of Lisa Fico with Evercore ISI. Please go ahead.

Our next question comes from the line of Lisa FICO with Evercore ISI. Please go ahead.

Speaker 10: Hi, this is Jamie for Lisa. Thanks for taking our questions. So, I have two questions. So, one is, maybe I've missed it in the prepared remarks, but can you give us an update on your clinical hold for LacudaMap, and then my second question is for your PTCO update at ASH. What should be, what will be an appropriate benchmark for this data? Thank you.

Hi, This is Danny on for Lisa Thanks for taking our questions.

I have two questions. One is maybe ask Mr. In the prepared with lifestyle can you give us an update on your clinical hold final cleared them up and then my second question is for your PTC I'll update at Ash.

Sure.

It will be.

Appropriate benchmarks that does data thank you.

Speaker 8: Okay, the first question is about Lacrytamab clinical hold, you said, I think, and probably it's time and opportunity for Sonia to provide an update on the partial clinical hold for Lacrytamab, and then I'll take the question on PDCS.

Okay. The first question.

It was about like with them up.

I'll hold you said I think in probably it's time and opportunity for Sonya to provide an update on the partial clinical hold for equity come up and then I'll take the question on Pts.

Speaker 4: Certainly. As mentioned before, the FDA placed the partial clinical hold due to one case of HLH that was reported in one subject.

So do you think.

Certainly.

As mentioned before.

The FDA it's Mike.

Partial clinical hold due to one off extra light that was reported in one target.

Speaker 4: We, of course, intend to lift the partial hold as soon as possible once the FDA requests have all been satisfied. However, this clinical hold or partial hold does not impact the telomere timelines because the recruitment in both mycotis fungoides and cesare has been completed and the final data are imminent.

<unk>.

We of course intend to.

Lifted the partial hold as soon as possible once the FDA requests have all been satisfied.

I'll add on these clinical halls or partial hold does not impact the panamax timelines because the recruitment in both nikolas from Reuters.

<unk> has been completed and the final data.

Imminent.

Speaker 4: And for the PTCL, we have also recruited the, let's say, first cohort of patients, and we are making an interim analysis of the data. And I have to remind that this HLH case that has been highlighted in the TELOMAC trial.

And for the PTC and we have also recruited.

Let's say first.

<unk> cohort of patients and we are.

Making an interim analysis of the.

The data and I have to remind you that this.

<unk> case, it has been highlighted in the telematics.

Speaker 4: is indeed related to a transformation of the cesarean into a larger lymphoma and as you probably know HLH is commonly reported as a complication of cutaneous tissue lymphoma.

Phil.

Is indeed.

<unk> two <unk> transformation of the sign study into largest on lymphoma, and as you probably know HLA E. Com only reported as a complication of cutaneous T cell lymphoma.

Speaker 8: Thank you, Sonia. So for the second question, so let me first maybe go back a few years ago when we finished phase one. At the time, we didn't have data outside.

Thank you Sonya so whats the second question. So let me first maybe go back a few years ago. When we finished phase one at the time, we didn't have.

Data outside Society syndrome.

Speaker 8: Most if not all the patients included in the phase one program had cesarean syndrome and of course the obvious question We are excited and we are still excited by the signal we've seen in cesarean patient but the main question was to see whether there is activity outside cesarean and the logic next step was to go in cutaneous T-cell lymphoma outside cesarean test

Most if not all the patients included in the Phase one program headsets already syndrome and of course. The obvious question. We are excited and we are still excited by the signal we've seen in <unk> patients, but the.

The main question was to see whether these activities outside sorry, and the logic next step for us to go in cutaneous T cell and T cell lymphoma outside so is already in test the drug in mycosis <unk> debt that was the priority number two and that's what we will be communicated at the end of the year as we said we are on track.

Speaker 8: the drug in mycosis bongiostasis. That was the priority number two, and that's what we will be communicating at the end of the year. As we said, we are on track to have the final data in-house in mycosis bongiostasis. But from the data published, the interim data published last year and updated even recently this year, we are confident that the signal is present actually when K3-DL2 is expressed.

To have the final data in house in Mycosis, <unk>, but from the data published the interim data published last year and updated even recently this year, we are confident that the signal.

Is present actually when Q3 deal too is expressive and hence the potential for lack of them up to be used to be used in the treatment of peripheral T cell lymphoma, I remind you that almost half of the patients with <unk>.

Speaker 8: Hence, the potential for Lexidemab to be used in the treatment of peripheral T-cell lymphoma. I remind you that almost half of the patients with PTCL do express K3DL2. We are running two trials in the difficult to treat relapsed refractory setting. One is a company-sponsored trial. Mainly a safety phase 1b trial that we are conducting and for which we will present an update.

Do you expect Q3 deal too.

We are running two trials in the difficult to treat relapsed refractory setting.

One is.

A company sponsored trial.

Mainly a safety phase one b trial that we are conducting and for which we will presented to date.

Speaker 8: in a couple of weeks at Ash and the second trial is a

A couple of weeks at Ash and the second trial as is.

Speaker 8: an investigator-sponsored trial performed in collaboration with the LISA group, and it's a combination trial. And I think the combination strategy in particular in the relapse refractory is something very important. We are, of course, excited by the clinical data that we have generated and that we will be.

An investigator sponsored trial.

<unk> in collaboration with the Liza group and it's a combination trial and I think the combination.

Our strategy in.

Particular in the relapse refractory is something very important.

There are of course excited by the preclinical data that we have generated and that will be.

Speaker 11: published at ASH, as I said, in a couple of weeks. We remain optimistic about the potential to run combination trials in the relapse refractory setting, but also in first line. And the plan, of course, is to expand the development of laquitamab in peripheral T-cell lymphoma beyond the difficult-to-treat relapse refractory, but that's the first step.

<unk>.

<unk>.

As I said in a couple of weeks, we remain optimistic about the potential to run combination trials in the relapse refractory.

Setting, but also in first line and the plan of course is too.

Expand the development of <unk>.

<unk> been very proud T cell lymphoma beyond the difficult to treat relapse refractory, but that's the first step.

Got it thank you.

Yeah.

Speaker 1: There are no further questions at this time. I would now like to turn the call over to Maunder Madhubi for closing remarks.

There are no further questions at this time I would now like to turn the call over to monitor <unk> for closing remarks.

Speaker 8: As a concluding remark, I would say, A, we are very encouraged by the robust outcomes of Lakedama in heavily pre-treated patients with Cesare's syndrome. Discussions with the FDA will enable us to evaluate the potential for accelerated approval and to firm up phase three plans.

Thank you.

As a closing concluding remark I would say we are.

Very encouraged by the robust outcomes.

<unk> been heavily pre treated.

With <unk> syndrome.

Discussions with the FDA will enable us to evaluate the potential products related approval and to firm up phase III plans.

Speaker 8: We are, of course, in ongoing dialogue with potential partners that can realize the full potential of the drug for patients with T-cell lymphoma, both cutaneous and peripheral T-cell lymphoma.

We are of course in <unk>.

Ongoing dialog with potential partners that can realize the full potential of the drug for patients with T cell lymphoma, both cutaneous.

Speaker 8: Second message, we are making great progress with our early stage pipeline. Pleased to see the progress of APH 61 or SAR 579 in AML with an update.

T cell lymphoma.

Second message, we are making great progress with our early stage pipeline. Please to see the progress of <unk> 61, a SAR, 579% with an update.

Speaker 8: at the upcoming ASH, pleased to announce that we have cleared the IND for APS65 and we are waiting for the start of the phase one this year. And finally, as you've heard from Yanis, excited by our differentiated anti-Niktin 4 ADC with a top 1 payload, which is moving toward IND next year.

At the upcoming Ash.

Please to announce that we had cleared the IND for <unk> 65, and we are waiting for the start of the phase one this year and finally as you've heard from me and is excited by our differentiated anti <unk> four ADC with a top one payload, which is moving towards R&D next year loss, but noticed.

Speaker 8: Last but not least, sufficient cash to fund the operation into H2 next year, with, as of end of September , 122 million euros.

<unk> sufficient cash to fund operation into <unk> next year with as of end of September 122 million euros.

Speaker 8: 25. So yeah, some cash in each to 2025. Thank you very much.

25, <unk> <unk> 2025, thank you very much.

Speaker 1: I would like to thank our speakers for today's presentation and thank you all for joining us. This now concludes today's call and you may now disconnect.

I would like to thank our speakers for today's presentation and thank you all for joining US just now concludes today's call and you may now disconnect.

Speaker 12: Please wait. The conference will begin shortly. Please stand by. The conference will begin shortly.

Please wait the conference will begin shortly.

[music].

Okay.

Okay.

[music].

Yes.

Yes.

Okay.

Yes.

Yes.

[music].

Okay.

Yes.

[music].

Okay.

Okay.

[music].